The company's connected devices and mobile apps engage and empower respiratory patients by measuring lung function and tracking adherence.
Available as a free download, the app relies on evidence-based care guidelines to empower COPD patients to better monitor and manage their condition.
The former is looking to use data for the early detection of arrhythmia and cerebral infarction, while the latter aims to collect data from people with COPD.
GSK will use the sensor in the studies to automatically collect and record data on the inhaler's usage, and wirelessly transmit the data collected.
Hospital readmission is typically very high for COPD patients, with about 20% of them getting readmitted within 30 days due to complications.
The program will help patients complete pulmonary rehabilitation (PR) exercises at home; PR is considered an essential component of COPD care.
FDA-approved marketing claims of improved adherence and reduction in exacerbations address key unmet needs in respiratory health.
With Adherium's smartphone-connected device, the medication adherence increases by up to 59% in adults and 180% in children with asthma.
The Bluetooth-enabled, smartphone-connected device measures critical lung function with comparable accuracy to clinical-grade spirometers.
The two parties will start with focus on chronic obstructive pulmonary disease (COPD) to make it easier for doctors and patients to work together.